Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
6 - Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
Published online by Cambridge University Press: 05 March 2016
Book contents
- Managing Myeloproliferative Neoplasms
- Managing Myeloproliferative Neoplasms
- Copyright page
- Contents
- Contributors
- Preface
- 1 Initial assessment of the undiagnosed patient who has an erythrocytosis, leukocytosis, or thrombocytosis
- 2 Practical approaches to molecular testing and diagnosis of mastocytosis, hypereosinophilia, and MDS/MPN overlap syndromes
- 3 Incidental splenomegaly: an approach to diagnosis
- 4 When to do a bone marrow biopsy and how to interpret it in the diagnosis of myeloproliferative neoplasm
- 5 Accurately assessing risk in your myeloproliferative neoplasm patient
- 6 Incorporating symptomatic assessment in therapy choice for patients with myeloproliferative neoplasms
- 7 The newly diagnosed patient with essential thrombocythemia
- 8 The newly diagnosed patient with polycythemia vera
- 9 Longstanding polycythemia vera and essential thrombocythemia: monitoring and management goals
- 10 Which patients are candidates for JAK inhibitors and how to manage patients on JAK inhibitor treatment
- 11 Hematopoietic cell transplantation for myelofibrosis: who and when?
- 12 Systemic mast cell disease: diagnosis and management
- 13 Hypereosinophilia: an illustrated approach to diagnosis and management
- 14 Myelodysplastic/myeloproliferative neoplasm overlap syndromes
- 15 Atypical chronic myeloid leukemia and chronic neutrophilic leukemia
- 16 Women and children with myeloproliferative neoplasms – special considerations
- 17 Conception and pregnancy in myeloproliferative neoplasms
- 18 Managing acute vascular events in patients with myeloproliferative neoplasms
- 19 Challenging thrombotic scenarios in the myeloproliferative neoplasms: splanchnic vein thrombosis and others
- 20 Familial myeloproliferative neoplasms – implications for patients and their families
- 21 Management of acute leukemia following myeloproliferative neoplasms
- Index
- References
Summary
A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
- Type
- Chapter
- Information
- Managing Myeloproliferative NeoplasmsA Case-Based Approach, pp. 45 - 55Publisher: Cambridge University PressPrint publication year: 2016
References
Barbui, T, Barosi, G, Birgegard, G, Cervantes, F, Finazzi, G, Griesshammer, M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761–70.CrossRefGoogle ScholarPubMed
Passamonti, F, Thiele, J, Girodon, F, Rumi, E, Carobbio, A, Gisslinger, H, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012;120(6):1197–201.CrossRefGoogle Scholar
Mesa, RA, Niblack, J, Wadleigh, M, Verstovsek, S, Camoriano, J, Barnes, S, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer. 2007;109(1):68–76.CrossRefGoogle ScholarPubMed
Mesa, RA, Schwager, S, Radia, D, Cheville, A, Hussein, K, Niblack, J, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res. 2009;33(9):1199–203.CrossRefGoogle ScholarPubMed
Scherber, R, Dueck, AC, Johansson, P, Barbui, T, Barosi, G, Vannucchi, AM, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood. 2011;118(2):401–8.CrossRefGoogle ScholarPubMed
Emanuel, RM, Dueck, AC, Geyer, HL, Kiladjian, JJ, Slot, S, Zweegman, S, et al. Myeloproliferative Neoplasm (MPN) Symptom Assessment Form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098–103.CrossRefGoogle ScholarPubMed
Emanuel, R, Dueck, AC, Geyer, HL, Kiladjian, J-J, Slot, S, Zweegman, S, et al. Myeloproliferative (MPN) symptom burden response thresholds: assessment of MPN-SAF TSS quartiles as potential markers of symptom response. Blood. 2013;122(21).CrossRefGoogle Scholar
Geyer, HL, Emanuel, RM, Dueck, AC, Kiladjian, JJ, Xiao, Z, Slot, S, et al. Distinct clustering of symptomatic burden amongst myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. Blood. 2014;123(24):3803–10.CrossRefGoogle Scholar
Nangalia, J, Massie, CE, Baxter, EJ, Nice, FL, Gundem, G, Wedge, DC, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med. 2013;369(25):2391–405.CrossRefGoogle ScholarPubMed
Klampfl, T, Gisslinger, H, Harutyunyan, AS, Nivarthi, H, Rumi, E, Milosevic, JD, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379–90.CrossRefGoogle ScholarPubMed
Rumi, E, Pietra, D, Ferretti, V, Klampfl, T, Harutyunyan, AS, Milosevic, JD, et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123(10):1544–51.CrossRefGoogle ScholarPubMed
Verger, E, Dosquet, C, Andreoli, A, Schlageter M, H, Chomienne, C, Kiladjian, Je-J. Clinical and molecular response to interferon alpha therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015. (in press).CrossRefGoogle ScholarPubMed
Tefferi, A, Rumi, E, Finazzi, G, Gisslinger, H, Vannucchi, AM, Rodeghiero, F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874–81.CrossRefGoogle ScholarPubMed
Landolfi, R, Marchioli, R, Kutti, J, Gisslinger, H, Tognoni, G, Patrono, C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114–24.CrossRefGoogle ScholarPubMed
Marchioli, R, Finazzi, G, Specchia, G, Masciulli, A, Mennitto, MR, Barbui, T. The CYTO-PV: a large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events in patients with polycythemia vera. Thrombosis. 2011;2011 :794240.Google Scholar
Barosi, G, Mesa, R, Finazzi, G, Harrison, C, Kiladijan, JJ, Lengfelder, E, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013;121:4778–81.CrossRefGoogle ScholarPubMed
Verstovsek, S, Mesa, RA, Gotlib, J, Levy, RS, Gupta, V, DiPersio, JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799–807.CrossRefGoogle ScholarPubMed
Harrison, C, Kiladjian, JJ, Al-Ali, HK, Gisslinger, H, Waltzman, R, Stalbovskaya, V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366(9):787–98.CrossRefGoogle ScholarPubMed
Verstovsek, S, Passamonti, F, Rambaldi, A, Barosi, G, Rosen, PJ, Rumi, E, et al. A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014;120(4):513–20.CrossRefGoogle ScholarPubMed
Vannucchi, A, Kiladjian, J-J, Griesshammer, M, Masszi, T, Durrant, S, Passamonti, F, et al. Results of a prospective, randomized, open-label phase III study of ruxolitinib in polycythemia vera patients resistant to or intolerant of hydroxyurea: the RESPONSE trial. European Hematology Association Annual Meeting Abstracts Oral Presentation. 2014. Abstract #LB-2436.Google Scholar
Cervantes, F, Passamonti, F, Barosi, G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia. 2008;22(5):905–14.CrossRefGoogle ScholarPubMed
Vaidya, R, Siragusa, S, Huang, J, Schwager, SM, Hanson, CA, Hussein, K, et al. Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years. Mayo Clinic Proc. 2009;84(12):1114–19.CrossRefGoogle ScholarPubMed
Hussein, K, Van Dyke, DL, Tefferi, A. Conventional cytogenetics in myelofibrosis: literature review and discussion. Eur J Haematol. 2009;82(5):329–38.CrossRefGoogle ScholarPubMed
Passamonti, F, Rumi, E, Caramella, M, Elena, C, Arcaini, L, Boveri, E, et al. A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis. Blood. 2008;111(7):3383–7.CrossRefGoogle ScholarPubMed
Tefferi, A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am. J Hematol. 2013;88(2):141–50.Google ScholarPubMed
Vannucchi, AM. Management of myelofibrosis. Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program. 2011;2011:222–30.Google Scholar
Guglielmelli, P, Barosi, G, Rambaldi, A, Marchioli, R, Masciulli, A, Tozzi, L, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood. 2011;118(8):2069–76.CrossRefGoogle Scholar
Pardanani, A CD, George, G, Lasho, L, Hogan, W, Litzow, M, Begna, K, et al. Safety and efficacy of CYT387, a JAK-1/2 inhibitor, for the treatment of myelofibrosis. J Clin Oncol. 2011;29(suppl; abstract 6514).CrossRefGoogle Scholar
Harrison, CN, Niederwieser, D, Vannucchi, A, Kiladjian, J-J, Barbui, T, Gisslinger, H, et al. Results from a 3.5 year update of COMFORT-II, a phase 3 study comparing ruxolitinib (Rux) with best available therapy (BAT) for the treatment of myelofibrosis. European Hematology Association Annual Meeting Abstracts (P403). 2014.Google Scholar
Tefferi, A, Verstovsek, S, Barosi, G, Passamonti, F, Roboz, GJ, Gisslinger, H, et al. Pomalidomide is active in the treatment of anemia associated with myelofibrosis. J Clin Oncol. 2009;27(27):4563–9.CrossRefGoogle ScholarPubMed
Quintas-Cardama, A, Vaddi, K, Liu, P, Manshouri, T, Li, J, Scherle, PA, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109–17.CrossRefGoogle ScholarPubMed
Verstovsek, S, Kantarjian, H, Pardanani, AD, Thomas, D, Cortes, J, Mesa, R, et al. The JAK inhibitor INCB018424 demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia/essential thrombocythemia myelofibrosis (post-PV/ET-MF). Blood. 2008;112(suppl; abstract 1762).CrossRefGoogle Scholar
Verstovsek, S, Dean, JP, Cernohous, P, Komrokji, RS, Seymour, JF, Mesa, RA, et al. Pacritinib, a dual JAK2/FLT3 inhibitor: an integrated efficacy and safety analysis of phase II trial data in patients with primary and secondary myelofibrosis (MF) and platelet counts ≤100,000/µl. Blood. 2013;122(21):395.CrossRefGoogle Scholar
Thapaliya, P, Tefferi, A, Pardanani, A, Steensma, DP, Camoriano, J, Wu, W, et al. International working group for myelofibrosis research and treatment response assessment and long-term follow-up of 50 myelofibrosis patients treated with thalidomide-prednisone based regimens. Am J Hematol. 2011;86(1):96–8.CrossRefGoogle Scholar
Tefferi, A, Cortes, J, Verstovsek, S, Mesa, RA, Thomas, D, Lasho, TL, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood. 2006;108(4):1158–64.CrossRefGoogle ScholarPubMed
Guglielmelli, P, Barosi, G, Rambaldi, A, Marchioli, R, Masciulli, A, Tozzi, L, et al. Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood. 2011;118(8):2069–76.CrossRefGoogle Scholar
Rambaldi, A, Dellacasa, CM, Finazzi, G, Carobbio, A, Ferrari, ML, Guglielmelli, P, et al. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010;150(4):446–55.CrossRefGoogle ScholarPubMed
DeAngelo, DJ, Mesa, RA, Fiskus, W, Tefferi, A, Paley, C, Wadleigh, M, et al. Phase II trial of panobinostat, an oral pan-deacetylase inhibitor in patients with primary myelofibrosis, post-essential thrombocythaemia, and post-polycythaemia vera myelofibrosis. Br J Haematol. 2013;162(3):326–35.CrossRefGoogle ScholarPubMed
Ballen, KK, Shrestha, S, Sobocinski, KA, Zhang, MJ, Bashey, A, Bolwell, BJ, et al. Outcome of transplantation for myelofibrosis. Biol Blood Marrow Transplant. 2010;16(3):358–67.CrossRefGoogle ScholarPubMed
Tam, CS, Nussenzveig, RM, Popat, U, Bueso-Ramos, CE, Thomas, DA, Cortes, JA, et al. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood. 2008;112(5):1628–37.CrossRefGoogle ScholarPubMed
Tefferi, A, Cervantes, F, Mesa, R, Passamonti, F, Verstovsek, S, Vannucchi, AM, et al. Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. Blood. 2013;122(8):1395–8.CrossRefGoogle ScholarPubMed